Not all oncologists bring up fertility implications, says study

Findings recently published in Practical Radiation Oncology could have enormous implications for young lymphoma patients, especially those diagnosed with Hodgkin's lymphoma.

The findings indicate that whether the issue of potential infertility as a complication of cancer treatment is discussed by one's doctor has a lot to do with his or her oncology specialty.

 

Surgical oncologists tend to nelgect the fertility issue

Patients of reproductive age should not necessarily count on the oncology doctor to bring up fertility implications, but they can count on about four in every five radiation oncologists and medical oncologists to bring up the issue in consultation.

However, only about half of surgical oncologists do so. Fortunately, it is uncommon for any lymphoma patients to be treated by surgical oncologists.

These same figures apply to which specialists are prone to refer of-age patients to infertility specialists or reproductive endocrinologists.

Why is this issue overlooked?

As for why surgical oncologists often don't raise the issue of fertility, researchers could only speculate that it might be due to

  • Less interaction time with patients
  • Assumption that it's been discussed by a previous provider
  • The belief that surgery doesn't present the same risk to fertility as chemotherapy or radiation.

Source: CancerTreatment.net

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap